Intratumoral anti-CTLA-4 therapy: Enhancing efficacy while avoiding toxicity

Aurelien Marabelle; Holbrook Kohrt; Ronald Levy

doi:10.1158/1078-0432.CCR-13-1923

Intratumoral anti-CTLA-4 therapy: Enhancing efficacy while avoiding toxicity

Aurelien Marabelle, Holbrook Kohrt, Ronald Levy

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

49 Citations (Scopus)

Résumé

Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

langue originale	Anglais
Pages (de - à)	5261-5263
Nombre de pages	3
journal	Clinical Cancer Research
Volume	19
Numéro de publication	19
Les DOIs	https://doi.org/10.1158/1078-0432.CCR-13-1923
état	Publié - 1 oct. 2013
Modification externe	Oui

Accès au document

10.1158/1078-0432.CCR-13-1923

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{bcc9bf6a37b34fe39b913b54ce34ca78,

title = "Intratumoral anti-CTLA-4 therapy: Enhancing efficacy while avoiding toxicity",

abstract = "Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.",

author = "Aurelien Marabelle and Holbrook Kohrt and Ronald Levy",

year = "2013",

month = oct,

day = "1",

doi = "10.1158/1078-0432.CCR-13-1923",

language = "English",

volume = "19",

pages = "5261--5263",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "19",

}

TY - JOUR

T1 - Intratumoral anti-CTLA-4 therapy

T2 - Enhancing efficacy while avoiding toxicity

AU - Marabelle, Aurelien

AU - Kohrt, Holbrook

AU - Levy, Ronald

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

AB - Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

UR - https://www.scopus.com/pages/publications/84886405297

U2 - 10.1158/1078-0432.CCR-13-1923

DO - 10.1158/1078-0432.CCR-13-1923

M3 - Article

C2 - 23965900

AN - SCOPUS:84886405297

SN - 1078-0432

VL - 19

SP - 5261

EP - 5263

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 19

ER -